Market News AIOpen the app

STLN stock news · Starling Oncology

Stories about Starling Oncology (STLN) from the last 90 days, each explained in plain English with whether the news reads good or bad for the company.

Get alerts for STLN

Follow Starling Oncology (STLN) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for STLN
Free on the App Store and Google Play, or on the web.
  1. Nov 5, 2026, 5:55 PM ET · Market

    Starling Oncology shared its third-quarter results, showing record sales of $169.8 million, up 24% from last year.

    Good for STLN

    Starling Oncology reported Q3 sales of $169.8 million, up 24%, and adjusted EBITDA of $3.4 million, above its earlier forecast range. This points to a stronger outlook.

  2. Aug 21, 2026, 5:31 PM ET · Market

    Starling Oncology, Inc. announces the establishment of a significant definitive agreement (STLNW).

    Good for STLN

    Starling Oncology, Inc. has filed a Form 8-K indicating its entry into a material definitive agreement, which suggests a strategic move that could bolster its financial standing and operational capacity. This development is likely to be viewed positively by investors as it may lead to enhanced growth opportunities.